Epocrates to boost mobile healthcare support tools with IPO:
This article was originally published in Clinica
Epocrates, a developer of mobile decision support software for the healthcare sector, is looking to raise $75m through an IPO on the Nasdaq Stock Exchange. The firm provides healthcare software that doctors can load onto hand-held, electronic point-of-care devices, such as PDAs or smartphones, and use to help in their clinical decision-making to enhance patient safety, comply with clinical standards of care, improve practice productivity, and better manage information. According to Epocrates, 50% of physicians use devices such as PDAs or smartphones in the US. The San Mateo, California-based firm will list under the ticker symbol "EPOC".
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.